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BETA-GLOBIN GENE CLUSTER HAPLOTYPES IN SICKLE CELL DISEASE; 
POLYMORPHISMS OF THE ARAB INDIAN HAPLOTYPE 
QUINTO GESIOTTO 
ABSTRACT 
 The HbS gene had a limited number of origins during history, and these 
can be defined by the haplotype (a set of DNA polymorphisms inherited together) 
of the associated β-globin gene. Five major haplotypes have been identified, and 
associated with different ethnic groups. These are the Arab Indian haplotype, the 
Benin haplotype, the Cameroonian haplotype, the Central African Republic 
(CAR) or Bantu haplotype, and the Senegal haplotype. The polymorphisms 
defining these haplotypes are associated with fetal hemoglobin, the major 
modifier of sickle cell disease phenotype and severity. The Arab Indian 
haplotype, in particular, is associated with unusually high HbF levels (20%), and 
a significantly less severe clinical presentation. We found a novel (C>T) SNP -68 
bp 5’ to HBD in this region, expressed in patients with the Arab Indian haplotype, 
but not sickle cell disease patients expressing other β-globin cluster haplotypes. 
There is evidence that this -68 (C>T) polymorphism may play a functional role in 
the hemoglobin expression of these patients, and its effect on globin levels and 
disease severity is the long-term interest of this study. A previous reporter assay 
in K562 cells determined that the -68 SNP was associated with decreased δ-
globin gene expression. This study aims to clone the HBD region of a patient 
positive for this SNP into a lentiviral firefly luciferase reporter vector, for use in 
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more physiologically accurate CD34+ erythropoietic progenitor cells. If the 
mutations in these β-globin gene haplotypes, such as the HBD mutation 
described in this study, are responsible for the protective effects seen in patients, 
perhaps some of these genetic locations can serve as targets for therapeutics in 
sickle cell disease or other blood disorders. 
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INTRODUCTION 
Hemoglobin, structure, function, synthesis 
 Hemoglobin (Hb), an iron-containing molecule composed of 2 pairs of 
unlike subunits, is responsible for transporting oxygen in the blood of vertebrates 
and some invertebrates. Oxygenation of hemoglobin takes place in the 
pulmonary capillaries, where oxygen binds to the heme groups of the hemoglobin 
molecule to form oxyhemoglobin (Hsia, 1998). 
In addition to oxygen, hemoglobin aids in transporting some of the body’s 
other gases. About 10% of the body’s respiratory carbon dioxide is bound to 
hemoglobin in the form of carbaminohemoglobin, in addition to the 85% being 
carried as bicarbonate. Nitric oxide also binds to some of the sulfydral groups of 
hemoglobin. When hemoglobin binds to oxygen in the lungs, its affinity for NO is 
increased, and both molecules are bound. As oxygen is released in peripheral 
tissues, NO affinity is reduced, and NO is unloaded as well (Hsia, 1998). This NO 
presence increases vasodilation, and thus decreases vascular resistance in 
these hypoxic regions.  
 Two pairs of unlike globin subunits combine to form a tetrameric 
hemoglobin. Each of these protein subunits consists of a protein chain, tightly 
bound to a non-protein heme group (an Fe2+ ion within an organic porphyrin 
ring). The main subunit types in humans are α, β, δ, ε, γ, and ζ (Table 1). In the 
embryonic period of development, four types of hemoglobin are present: 
Hemoglobin Gower 1 (two ζ and two ε subunits), Hemoglobin Gower 2 (two α 
	  2 
and two ε subunits), Hemoglobin Portland 1 (two ζ and two γ subunits), and 
Hemoglobin Portland 2 (two ζ and two β subunits) (Al-Mufti, Hambley, Farzaneh, 
& Nicolaides, 2000). During the fetal period, oxygen is carried by fetal 
hemoglobin (HbF), composed of two α globin and two γ globin chains, in addition 
to increasing amounts of adult hemoglobin (HbA. HbF has a higher oxygen 
affinity than HbA, due to its lack of interaction with 2,3-BPG, a molecule that 
decreases hemoglobin affinity for oxygen (Kwasiborski, Kowalczyk, Zieliński, 
Przybylski, & Cwetsch, 2010). HbF is found in erythroid precursors and mature 
erythrocytes called F-cells. After birth, HbF is found in trace amounts in the 
bloodstream, with most normal adults having <1% HbF and 0.3-4.4% F-cells 
(Rochette, Craig, & Thein, 1994). However, HbF levels are usually increased in 
sickle cell disease or β thalassemia. HbA, the most common type in adults, is 
composed of two α subunits and two β subunits. HbA makes up about 95% of 
adult hemoglobin content. Hemoglobin A2 (HbA2) is found in trace amounts in 
adults (1.5-3.5%), and is composed of two α and two δ subunits. HbA2 levels 
may be increased in patients with β thalassemia and assist in the diagnosis of 
carriers. Because of its low concentrations it has no known physiological 
function. 
The genes encoding the non-α globin subunits are grouped in close 
proximity on chromosome 11, in a gene grouping known as the human β-globin 
locus. This locus contains genes for β globin, δ globin, ε globin, and the two 
types of γ globin (γA and γG), in the order of 5’  ε  γG  γA  δ  β   
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Hb Type Globin Composition Time of production 
Gower 1 ζ2ε2 Embryo 
Gower 2 α2ε2 Embryo 
Portland 1 ζ2γ2 Embryo 
Portland 2 ζ2β2 Embryo 
HbF α2γ2 Fetus/Adult 
HbA α2β2 Adult 
HbA2 α2δ2 Adult 
Table 1. Hemoglobins, their chain composition, and period of production.  	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3’ that mimics their expression from embryonic to fetal to adult life (Figure 1) 
(Kiefer, Hou, Little, & Dean, 2008). The other subunits (ζ globin, α globin 1, and α 
globin 2) are encoded by the α-globin gene locus (Kiefer et al., 2008). The locus 
control region (LCR) is an erythroid-specific enhancer that partially controls the 
expression of each of these genes as they are differentially expressed 
throughout development, especially through fetal development and shortly after 
birth (Levings & Bungert, 2002).  
A number of erythroid transcription factors bind to the β-globin locus 
directly, and play important roles in globin expression during development. 
GATA1, also known as GATA-binding factor 1, is required for expression of the 
γ-globin gene (Woon Kim, Kim, Geun Kim, & Kim, 2011). GATA1 most likely 
affects transcription through histone acetylation, by recruiting CBP (a 
transcription activating protein) to hypersensitive sites within the γ-globin 
promoter and LCR (Woon Kim et al., 2011). NFE2 is also required for γ-globin 
expression, and contributes to hypersensitivity site formation in the β-globin locus 
during fetal development (Woon Kim et al., 2011). A particular family of zinc-
finger DNA binding proteins, the Kruppel-like factors, are important during 
erythropoiesis. Erythroid Kruppel-like factor 1 (KLF1) plays a key role in 
regulation, and targets at least one gene on the β-globin locus during 
erythropoiesis (Hodge et al., 2006). Kruppel-like factor 2 (KLF2) has a similar 
function, and the regulation duties of these proteins may overlap, particularly  
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Figure	  1.	  Globin	  gene	  locations	  and	  hemoglobin	  switching	  during	  development.	  Relative	  locations	  of	  globin	  genes	  on	  the	  α	  -­‐	  and	  β	  -­‐	  globin	  loci,	  and	  subunit	  breakdown	  of	  hemoglobins	  present	  before	  and	  after	  birth.	  Figure	  adapted	  from	  (Levings	  &	  Bungert,	  2002).	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when controlling δ globin expression during fetal development (Basu et al., 
2005).  
Disorders of hemoglobin 
Hemoglobin composition of the red blood cell is dependent on the genetic 
expression of globin subunits. Therefore mutations that reduce the expression, or 
cause the absence of a globin subunit expression altogether, or interfere with the 
protein structure of a globin chain, can cause clinical disease that can range from 
mild to fatal. Hemoglobinopathies, defined here as disorders of the structure or 
synthesis of hemoglobin, are a family of genetic disorders in which the genetic 
defect, usually an autosomal co-dominant trait, leads to an abnormal structure of 
one of the globin chains in hemoglobin or the reduction in production of one of 
the normal globin chains, and produces pathological symptoms in the affected 
person (Weatherall & Clegg, 2001). Structural abnormalities sometimes lead to 
serious health consequences such as hemolytic anemia or vasculopathy. 
Hemoglobinopathies are most common in Africa, southeast Asia, and the 
Mediterranean; seven percent of the world’s population is estimated to be 
carriers, with 70% of the pathologic carriers being of African descent (Makani et 
al., 2007). Malaria is endemic in Africa, and its large sickle cell prevalence is the 
result of a protective effect seen in sickle cell carriers (Aidoo et al., 2002). While 
individuals homozygous for the sickle cell mutation are more susceptible to 
malaria infection than normal individuals, heterozygotes are actually protected 
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from fatal malaria infection, and the sickle cell mutation persists in the population 
through these carriers (Aidoo et al., 2002).  
Perhaps the most well known hemoglobinopathy is sickle cell disease. 
Sickle cell disease affects about 72,000 people in the United States, and about 2 
million are carriers (heterozygotes) (Creary, Williamson, & Kulkarni, 2007). In 
Africa, about 200,000 children are born with sickle cell disease yearly, and 
without access to the comprehensive medical care available in the United States 
(Makani et al., 2007). Despite the large number of affected citizens, the amount 
of research performed on the continent is insufficient, and most medical 
advances addressing the problem are made based on North American studies. 
For these reasons, death in early childhood is common in the African population 
(Makani et al., 2007).  
Sickle cell disease, an autosomal recessive disorder, results from a single-
nucleotide polymorphism (A to T) of the β-globin gene, which causes a glutamic 
acid  valine switch (GAG codon  GTG codon) at position 6. Hemoglobin that 
incorporates this new mutated protein chain is referred to as Hemoglobin S 
(HbS). During conditions of normal oxygen concentrations, the secondary, 
tertiary, and quaternary structures of hemoglobin all remain intact. Once the 
environment becomes hypoxic, the hydrophobic residues of the valine at position 
6 of the β globin associate with a hydrophobic patch formed by the deoxy form of 
the protein (Lippincott’s Illustrated Reviews, n.d.). This association causes the 
HbS molecules to “collapse” on themselves and form fibrous aggregates, 
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eventually decreasing the elasticity of the red blood cell membrane and causing 
a sickle-like shape in the affected erythrocytes (Lippincott’s Illustrated Reviews, 
n.d.). This polymerization is minor in individuals who are heterozygous for the 
sickle cell mutation, as the normal globin gene contributes about 60% of HbA in 
the cell. These individuals, known as carriers or sickle cell trait, often only exhibit 
symptoms during times of severe oxygen deprivation (such as high altitudes) or 
dehydration. In individuals homozygous for the HbS gene, red blood cells 
typically lose their elasticity as they become sickle-shaped, and their rigidity 
prevents them from travelling easily throughout the vasculature (Lippincott’s 
Illustrated Reviews, n.d.). This can lead to ischemia and vessel obstruction 
(Cassidy, Monroig, & Kovach, 2015) (Bartolucci & Galactéros, 2012). Destruction 
of the HbS-containing cells occurs much faster than healthy erythrocytes are 
replenished, leading to hemolytic anemia (Damanhouri et al., 2015). 
Fetal hemoglobin 
HbF level is the major modifier of sickle cell disease phenotype and 
severity, and hydroxyurea, an upregulator of HbF production, is often given to 
sickle cell patients with severe symptoms. The pharmacological mechanism of its 
effects is not totally understood, but the major effect of this drug is to induce 
increased levels of HbF (Sheehan et al., 2014). HbA2 has a similar effect to HbF 
on the polymerization of HbS, and therefore genes affecting the levels of δ globin 
could be a therapeutic target in sickle cell positive individuals although this is not 
therapeutically possible at the present time (Poillon, Kim, Rodgers, Noguchi, & 
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Schechter, 1993). Several single-nucleotide polymorphisms associated with 
HbA2 affect HbA2 levels through their effects on HbF (Griffin et al., 2014). These 
mutations are found in the HBS1L-MYB locus on chromosome 6q, which has 
shown involvement in erythroid development and induction of HbF. MYB, the 
proto-oncogenic protein encoded by the MYB gene, is itself a critical regulator of 
erythroid development (Stadhouders et al., 2014). A MYB enhancer in the HMIP-
2 region of HBS1L-MYB also modulates HbF expression, most likely through 
KLF1 activity and effects on erythropoiesis (Griffin et al., 2014). 
Genetic basis of sickle cell disease heterogeneity  
The HbS gene had a limited number of origins during history, and these 
can be defined by the haplotype (a set of DNA polymorphisms inherited together) 
of the associated β-globin gene. Five major haplotypes have been identified, and 
associated with different ethnic groups. These are the Arab Indian haplotype, the 
Benin haplotype, the Cameroonian haplotype, the Central African Republic 
(CAR) or Bantu haplotype, and the Senegal haplotype (Loggetto, 2013). The 
polymorphisms defining these haplotypes are associated with different HbF 
levels (Alsultan et al., 2012) (Ngo et al., 2013) (Rumaney et al., 2014). As a 
result of this variability, and other less well defined modifying factors, the Arab 
Indian and Senegal haplotypes are associated with a less severe clinical 
presentation compared with the Benin haplotype, with Bantu being the most 
severe (Liu et al., 2009). Sickle cell disease patients within these ethnic groups 
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also have polymorphisms in other genetic sites, such as the α-globin locus, which 
can also modify the phenotype of the disease (Rumaney et al., 2014).  
As an example, in Cameroonian sickle cell disease, patients typically 
present with a delayed onset of symptoms (Rumaney et al., 2014). This β-globin 
haplotype is characterized by an (AT)8(T)5 sequence in the -500 region of the β 
gene, a polymorphism distinct from the sequences of the identified Benin, Bantu, 
Senegal, or Arab Indian haplotypes (Lapouméroulie et al., 1992). In addition to 
this β-globin mutation, Cameroonian patients express characteristic 
polymorphisms in the HBS1L-MYB region. These polymorphisms, particularly the 
SNPs rs9399137, have been linked to HbF expression and clinical severity of the 
disease (Bitoungui, Ngogang, & Wonkam, 2015). There is also an association of 
α thalassemia, an impaired production of α globin subunit chains, with sickle cell 
disease in Cameroonians. These individuals are characterized by a 3.7kb α-
globin gene deletion, and express higher levels of both HbF and HbA2. This 
decreases intracellular HbS levels, and alleviates red blood cell sickling, 
ultimately reducing the destruction of red blood cells. These protective effects of 
α thalassemia are also seen in Cameroonian individuals homozygous for the 
Benin haplotype, or individuals heterozygous for Cameroonian/Benin haplotypes 
(Rumaney et al., 2014). 
Arab Indian haplotype of sickle cell disease 
We have a special interest in sickle cell disease in Saudi Arabia because 
of the very high HbF levels found in patients in the Eastern Province of this 
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country. Saudi sickle cell disease was first characterized in the Eastern Province 
in the 1960s (Lehmann, Maranjian, & Mourant, 1963). A country with a 
population of 24 million, Saudi Arabia has a relatively high sickle cell disease 
prevalence, ranging from 2% to 7% across the country based on information from 
newborn screening (Jastaniah, 2011). The Saudi Premarital Screening Program 
estimates that 4.2% of the adults are sickle cell carriers, and 0.26% have sickle 
cell disease. The same program noted that the Eastern Province had the highest 
prevalence, with about 17% sickle cell carriers and 1.2% with sickle cell disease 
(Alhamdan, Almazrou, Alswaidi, & Choudhry, 2007).  
Saudi Arabian sickle cell disease has two major forms: the Benin 
haplotype, associated with patients in the west, and the Arab Indian haplotype, 
associated with Eastern patients. The Benin haplotype is more clinically severe, 
and less often is linked to a co-inheritance of α thalassemia (Padmos et al., 
1991). The Benin haplotype, when compared to the Arab Indian haplotype, is 
also associated more with respiratory symptoms such as acute chest syndrome 
and recurrent acute chest syndrome, and other symptoms such as dactylitis and 
stroke (Jastaniah, 2011). Patients with the Benin haplotype also have lower HbF 
levels, which partially explains the clinical severity of their disease (Table 2) 
(Padmos et al., 1991). Patients with the Arab Indian haplotype, in contrast, have 
higher HbF levels (20%), and therefore are less clinically severe (Table 2). The 
Arab Indian haplotype is more often associated with α thalassemia, which also 
alleviates disease symptoms (Jastaniah, 2011). 
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Table 2. Comparison of disease phenotypes associated with the Saudi Arab Indian (East) and 
Benin (West) haplotypes. Taken from (Jastaniah, 2011). 	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The Arab Indian β-globin haplotype is characterized by several genetic markers. 
These include an Xmn1 restriction site polymorphism (C>T) 158bp 5’ to HBG2 
(rs7482144), and several other single-nucleotide polymorphisms and insertion 
and deletion polymorphisms (Table 3). These SNPs and insertions/deletions are 
important for identification because the Senegal haplotype also contains the 
Xmn1 restriction site polymorphism (Ngo et al., 2013). This collection of 
polymorphisms is associated with up-regulation of HbF, and subsequent down-
regulation of HbS, in patients with the Arab Indian haplotype. A characteristic 
(AC)2(AT)9(T)5 motif, located in the HBB – HBD intergenic region, binds BP1, a 
homeobox gene and controller of development during the embryonic period, 
more tightly than other β-globin haplotypes (Haga et al., 2000) (Ngo et al., 2013). 
This binding lowers HbS levels by reducing expression of HbS through a cis-
acting mechanism, and is associated with low HBB mRNA expression (Ngo et 
al., 2013).  A point mutation (C>T) -158bp to the HBG2 gene is present in nearly 
all Saudis with sickle cell disease or trait from the Eastern Province, and a large 
amount of normal Saudis (22%) (Miller et al., 1987). This substitution is possibly 
related to HbF production, but its function is not yet well understood and recent 
work showed that another single nucleotide polymorphism (SNP), rs10128556 
downstream of HBG1 was more strongly associated with HbF than the (C>T) -
158 bp to the HBG2 itself, and that conditioning the analysis on rs10128556 
rendered the effect of this SNP on HbF insignificant. This suggested that the  
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Location Polymorphism/Sequence Gene 
-530 5’ to HBB (6) (AC)2(AT)9(T)5 HBB-HBD intergenic 
region 
-1412 5’ to HBB (35) G(TTTTA)6TTTTG HBB-HBD intergenic 
region 
-68 5’ to HBD (137) C>T HBD-HBG1 intergenic 
region 
-222 5’ to HBG1 (30) AAGC insertion HBG1 promoter 
-158 5’ to HBG2 (137) C>T HBG2 promoter 
HS-2 Core  (TA)10(CA)2(TA)2CG(TA)12 Locus Control Region 
Table 3. Polymorphisms within the β-globin cluster region associated with the Arab 
Indian haplotype. The locations and sequences of several Arab Indian haplotype 
polymorphisms located within the β-globin cluster, including the locus control region. Adapted 
from (Ngo et al., 2013) 
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C>T) -158 bp to the HBG2 site is not the functional variant but that rs10128556 
or a variant in LD with it might be the functional variant (Galarneau et al., 2010). 
The Corfu δ/β thalassemia mutation, located upstream of the δ-globin 
gene, indicates that the HBD-HBG1 intergenic region is heavily involved in γ-
globin gene activation and suppression of β-globin expression (Chakalova et al., 
2005). Indeed, HBD contains a 3.5kb region near the 5’ portion which binds 
BCL11A, HDAC1, and GATA-1, silencers of HBG expression (Sankaran et al., 
2011).  
The 5’ HBD -68 SNP 
We found a novel (C>T) SNP -68 bp 5’ to HBD in this region, which is 
expressed in patients with the Arab Indian haplotype, but not sickle cell disease 
patients expressing other β-globin cluster haplotypes (Alsultan et al., 2012). 
Saudi patients who are sickle cell carriers are heterozygous for this mutation, and 
unaffected individuals (including family members) do not have a mutation.  
 There is evidence that this -68 (C>T) polymorphism may play a functional 
role in the hemoglobin expression of these patients, and its effect on globin levels 
and disease severity is the long-term interest of this study. Indeed, the SNP is 
located within a regulatory CCAAC box (CCAAC>TCAAC) in the HBD promoter, 
believed to be party responsible for the reduced HBD expression relative to HBB 
in normal individuals (Bouva, Harteveld, van Delft, & Giordano, 2006). In one 
individual, presence of the -68 (C>T) mutation was associated with lowered HbA2 
levels (2%) and a slightly increased HbF production (1.3%) (Bouva et al., 2006). 
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A reporter assay in K562 cells determined that the -68 SNP was associated with 
decreased δ-globin gene expression (Alsultan et al., 2012). However, K562 is a 
leukemia cell line, and a K562 cell does not accurately mirror an erythroid cell 
producing globin proteins at a physiological normal level (Lozzio & Lozzio, 1975). 
This study aims to clone the HBD region of a patient positive for this SNP into a 
lentiviral firefly luciferase reporter vector, for use in more physiologically accurate 
CD34+ erythropoietic progenitor cells. A lentiviral vector system was chosen due 
to its reported effectiveness in transfecting these CD34+ progenitor cells (Oki et 
al., 2001) (Uchida et al., 2011).  This vector will be used in reporter assays which 
gauge the effects of the -68 C>T HBD mutation, without other associated 
polymorphisms present in the Arab Indian haplotype, on δ-globin expression, and 
possibly any indirect effects on γ-globin and HbF expression.  
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METHODS 
 
Development of DNA Inserts 
 
 Hemoglobin δ gene DNA was obtained from two patients, both positive for 
sickle cell mutation. The Arab Indian patient DNA was positive for a single-
nucleotide polymorphism -68 base pairs 5’ to the HBD gene, while the wild type 
DNA was negative for this mutation. The HBD gene had originally been cloned 
into the Promega pGL3 luciferase reporter vector at the SmaI site (Figure 2).  
 The wild-type and mutant vectors were transformed into One Shot TOP10 
Chemically Competent E. Coli (Life Technologies), and incubated at 37°C 
overnight on LB + ampicillin plates. Bacterial colonies were then selected and 
grown overnight in LB broth/ampicillin at 37°C with no success. After another 
trial, PCR was performed using the original pGL3 vector as a template. A forward 
primer (5’ – AACACTAGTGCATATTCCCAGGAACTTCG – 3’) and reverse 
primer (5’ – GACGATAGTCATGCCCCGCG – 3’) were designed to amplify the 
HBD gene, luciferase gene, and Spe1 site as a single PCR product. The Fisher 
Thermo Scientific Extensor Long PCR Enzyme Mix kit was used, and gel 
electrophoresis was run on a 1.0% agarose plate. The fragment band was visible 
at the desired length (between 3 and 4 kb) (Figure 3), and was purified using the 
QIAquick PCR Purification Kit.  
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Figure 2. pGL3-Promotor Vector. HBD DNA was originally cloned into the Sma1 site (blue 
arrow) of the Promega pGL3 Luciferase Reporter Vector. Image taken from the 
manufacturer’s website: https://www.promega.com/products/reporter-assays-and-
transfection/reporter-vectors-and-cell-lines/pgl3-luciferase-reporter-vectors/ 
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 To ensure that the product was correct, and contained the desired 
mutations, DNA sequencing was performed on both the wild-type and mutant 
DNA products. After blasting the sequence to the National Center for 
Biotechnology Information human genome and mRNA reference, it was 
determined that the mutant DNA was indeed positive for a single nucleotide 
polymorphism (C>T) at the -68 site (Figure 4), but wild type DNA did not have 
this mutation. Therefore, these fragments were selected for restriction enzyme 
digestion. Both the wild type and mutant HBD PCR products were prepared for 
ligation by double digest, using Spe1 and BamH1 restriction enzymes (New 
England Biolabs). The double digestion reaction was run at 37°C for one hour, 
and purified using the QIAgen cleanup kit. 
 
Preparation of Lentiviral Vector for Ligation 
  In order to transfect CD34+ cell lines in the future, a lentiviral vector was 
chosen for cloning. The pHAGE-CMV-DsRed Express-UBC-eGFP-W, obtained 
from Kotton Labs, was selected for use (Figure 5). The vector was transformed 
into One Shot TOP10 Chemically Competent E. Coli (Life Technologies), and 
incubated at 37°C overnight on LB + ampicillin plates. Colonies were selected, 
and incubated in a shaker at 250rpm overnight in LB broth + ampicillin. The 
vector product was purified using the QIAGEN Spin Miniprep Kit. 
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Figure 3. Gel electrophoresis of mutant and wild type HBD gene + luc gene PCR 
products. Lanes from left to right: DNA reference ladder, wild type DNA without -68 HBD 
mutation, mutant DNA containing -68 HBD mutation. DNA bands are consistent with expected 
size (3kb). 	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Figure 4. Sequencing data confirms wild type and mutant HBD DNA. Top: Mutant HBD 
DNA was positive for -68 SNP (C>T). Bottom: Wild type HBD DNA does not contain -68 SNP. 	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Figure 5. Map of lentiviral pHAGE-CMV-DsRed Express-UBC-eGFP-W vector. Vector was 
digested with NEB Spe1 and BamH1 restriction enzymes at the 2213 and 3491 sites, 
respectively (marked with blue arrows). Obtained from Kotton Labs (Wilson et al., 2008). 	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 Once purified, the lentiviral vector was digested with the Spe1 and BamH1 
restriction enzymes, in order to create ligation sites for the HBD DNA. This 
decreased the vector size by 1278 base pairs. Digestion was performed for one 
hour. Afterwards, New England Biolabs calf intestinal alkaline phosphatase was 
added to dephosphorylate the 5’ ends of the linearized vector and reduce the 
possibility of self-ligation. The resulting product was visualized using gel 
electrophoresis, with the undigested vector added as a control. The smaller 
digestion product band appeared in the expected range of about 1.3kb, and the 
larger band was cut and purified using the QIAGEN QIAquick Gel Extraction Kit 
(Figure 6). DNA spectroscopy showed yield of 36.28ng/2µL. 
 
 
Ligation Reaction 
 
 The objective of the ligation reaction procedure was to ligate the digested 
HBD insert and lentiviral vector at the restriction enzyme sites using DNA ligase.  
New England Biolabs Quick Ligase enzyme and Quick Ligation Buffer were 
used. For the reaction, a 3:1 insert:vector molar ratio was prepared using 1µL of 
the Quick Ligase enzyme. The reaction was incubated at room temperature for 
five minutes, and then cooled on ice before direct transformation (2µL of the 
ligation product mix) into Life Technologies One Shot TOP10 Chemically 
Competent E. Coli. The cells were incubated overnight at 37°C on LB + ampicillin 
plates. Colonies were selected, and shaken overnight at   
 
	  24 
 	  	  
 
 
Figure 6. Gel electrophoresis of lentiviral vector restriction enzyme digestion and 
dephosphorylation product. From left to right: DNA reference ladder, double digestion 
product 1, control (undigested vector).  	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37°C. The product was purified using the QIAGEN QIAquick Spin Miniprep Kit, 
but no DNA product was present when analyzed using DNA spectroscopy. 
Based on the lack of product DNA, we questioned if the competent cells 
used were not ideal for lentiviral vector transformation. New England Biolabs 
Stable Competent E. Coli (High Efficiency) cells were obtained based on the 
manufacturer’s claim that this cell line is very effective for lentiviral vector cloning. 
The transformation was performed again, using another 2µL of the ligation 
product prepared previously. The product was purified using the QIAGEN 
QIAquick Spin Miniprep Kit, but was determined not to be the desired vector 
product. This was concluded after unsuccessful digestion using the restriction 
enzymes Spe1 and BamH1, in an attempt to reproduce the original digested 
HBD fragment PCR product. 
 
Two-step Vector Digestion 
Although a dephosphorylation step had been added to the end of the 
ligation reaction to prevent self-ligation, there was still possibility that the reaction 
was producing a self-ligation product. If true, the colonies selected could contain 
a vector product with the ampicillin resistance gene, but without the desired insert 
containing the HBD and firefly luciferase genes. To ensure that the vector had 
been digested properly, another double digestion was performed on the original 
pHAGE-CMV-DsRed Express-UBC-eGFP-W vector. A two-step reaction was 
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conducted, with separate steps for each restriction enzyme to maximize 
efficiency. 
In the first step, the lentiviral vector was digested using just the New 
England Biolabs Spe1 restriction enzyme (1µL), using New England Biolabs 
CutSmart buffer. The reaction was incubated in a water bath at 37°C for one 
hour. After initial digestion, 1µL of New England Biolabs BamH1 enzyme was 
added, as both enzymes have 100% activity in the CutSmart buffer. The reaction 
was incubated at 37°C for another two hours to ensure near complete digestion, 
after which calf intestinal phosphatase (New England Biolabs) was added to 
dephosphorylate the 5’ ends of the DNA and prevent self-ligation. The 
dephosphorylation reaction was allowed to run for 30 minutes. Agarose gel 
electrophoresis of the product mixture showed the expected band at about 1.2kb 
(Figure 7). The digested vector band was distinguishable in size from the 
undigested lentiviral vector, which was run on the same gel as a control.  Based 
on these results, it was determined that the vector had been digested 
successfully. The larger band was cut from the gel using a razor blade, and 
purified using the QIAGEN QIAquick Gel Extraction Kit. DNA spectroscopy of the 
purified product showed a DNA concentration of 12ng/µL. 
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Figure 7. Gel electrophoresis of lentiviral vector double digested with Spe1 and BamH1 
enzymes. Lanes from left to right: 1. DNA reference ladder 2. Digestion product-1 3. Digestion 
product-2 4. Control (undigested lentiviral vector) 	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Re-Digestion of HBD + luc DNA Inserts 
 Another double digestion reaction was performed to ensure the 
development of the desired insert product. The original PCR products for the 
mutant and wild type HBD genes were prepared for digestion by adding 1µL 
each of the Spe1 and BamH1 enzymes (New England Biolabs), in addition to the 
New England Biolabs CutSmart Buffer. For this reaction, the mixtures were 
incubated at 37°C for two hours, as opposed to the previous incubation time of 
one hour. After digestion, gel electrophoresis was run on the product (Figure 8). 
The mutant and wild type insert bands appeared at the expected length (3kb), 
with not much difference expected between the double digestion product and the 
original PCR product. Although the scale of the gel makes it very difficult to 
determine the ratio of undigested to digested product, it was determined that the 
insert length was correct and assumed that the fragment had been digested well 
enough to be useful in subsequent ligation. 
 
Ligation Reaction Using Two-Step Digestion Vector Product 
 A ligation reaction was prepared using the purified digested lentiviral 
vector product from the previous reaction, and each of the newly digested mutant 
and wild type DNA inserts. New England Biolabs DNA Ligase (1µL) was used, 
along with the New England Biolabs Quick Ligase Buffer (5µL). For the reaction, 
a 3:1 insert:vector molar ratio was used, based on the enzyme manufacturer’s  
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Figure 8. Gel electrophoresis of mutant and non-mutant insert DNA after 2-hour 
restriction enzyme digestion. Lanes from left to right: 1. DNA reference ladder 2. Wild type 
DNA 3. Mutant DNA. Insert bands for both the mutant and wild type were at desired length 
(3kb). 	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recommendation. The reaction was incubated at room temperature for five 
minutes, and cooled on ice before direct transformation using Stable Competent 
E. Coli (High Efficiency) cells (New England Biolabs). The cells were incubated 
overnight at 37°C on LB + ampicillin plates. The next day, very few colonies were 
present. However, no colonies were present on the negative control plate, so the 
possibility of ineffective ampicillin was ruled out and the experiment was 
continued. Colonies were selected, and shaken overnight in LB broth + ampicillin. 
Cells were lysed and the vector product was purified using the QIAGEN QIAquick 
Spin Miniprep Kit. When analyzed using DNA spectroscopy, no DNA product was 
present. Possible explanations for this include problems with vector and insert 
digestion, ligation problems, or contamination. 
 
Ligation Reaction with Increased Insert:Vector Molar Ratio 
 
 To rule out insufficient insert concentration as an explanation for poor 
ligation, another ligation reaction was performed using the previously digested 
vector and insert products. New England Biolabs Quick DNA Ligase (1µL) was 
used, along with the New England Biolabs Quick Ligase Buffer (5µL). For this 
reaction mixture, a 5:1 DNA insert:vector molar ratio was used, in an attempt to 
“oversaturate” the vector with insert DNA and force ligation. The reaction was 
carried out for 5 minutes at room temperature, and cooled on ice before 
immediate transformation into Stable Competent E. Coli (High Efficiency) cells 
(New England Biolabs). The cells were incubated overnight at 37°C on LB + 
ampicillin plates. The next day, colonies were selected and shaken overnight in 
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an incubator at 37°C. The DNA product was purified using QIAGEN QIAquick 
Spin Miniprep Kit, and PCR was performed in an attempt to obtain the original 
HBD DNA containing the mutation site. Gel electrophoresis revealed an 
undesired product (Figure 9).  
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Figure 9. Gel electrophoresis of PCR product: ligation reaction transformation product. 
Lanes from left to right: 1: DNA reference ladder, 2 and 3: Wild type DNA, 4 and 5: Mutant 
DNA. Bands revealed a product around 1.2kb, much less than the expected length of 3kb. 	  
	  33 
RESULTS 
 
 The first step in determining the feasibility of developing this lentiviral 
luciferase reporter vector containing the human δ-globin gene was to obtain both 
the mutant and non-mutant genes, and verify their identity. The Saudi and non-
Saudi patient DNA was sequenced, and the Saudi patient was determined to 
have a single nucleotide polymorphism (C>T) -68 bp 5’ of HBD, a characteristic 
point mutation of the Arab Indian β-globin cluster haplotype.  
 The pHAGE-CMV-DsRed Express-UBC-eGFP-W vector was successfully 
transformed into E. Coli, and subsequent digestion using the restriction enzymes 
Spe1 and BamH1 was successful. This was verified by agarose gel 
electrophoresis.  
 Ligation of the double digestion products of the vector and insert DNA 
proved difficult. One possibility was incomplete digestion with restriction 
enzymes, Spe1 and BamH1. This was addressed first by digesting the vector in a 
two-step process, using each enzyme individually. This increased the overall  
reaction time, and allowed for more enzyme activity. The insert DNA digestion 
time was also increased, with no observable effect on ligation success. Another 
possibility was self-ligation, a problem we tried to prevent using the New England 
Biolabs dephosphorylating enzyme calf intestinal phosphatase. While effective, 
this enzyme doesn’t ensure complete removal of all 5’ phosphate groups in the 
vector DNA, leaving the reaction vulnerable to self-ligation products. The 
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insert:vector DNA molar ratio was also increased from 3:1 to 5:1, in an attempt to 
decrease the chance of obtaining self-ligation product.  
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DISCUSSION 
 
The goal of this experiment was to develop a pair of lentiviral vectors 
containing HBD DNA, which could eventually be used to assess the effects of the 
single nucleotide polymorphism (C>T) -68 bp 5’ of HBD on δ-globin expression in 
primary erythroid CD34+ cells. This mutation is characteristic of the Arab Indian 
β-globin cluster haplotype, typically seen in Saudi Arabian sickle cell disease 
patients (Ngo et al., 2013). These patients, compared to sickle cell patients with 
other haplotypes, have more mild symptoms and an increased survival rate, due 
to their upregulated production of HbF (Jastaniah, 2011). The genetic 
modifications characteristic of the Arab Indian β-globin cluster haplotype most 
likely play a role in this altered globin production (Alsultan et al., 2012).  
The intergenic region where this -68 single nucleotide polymorphism is 
located contains important modulatory genes for HbF expression (Sankaran et 
al., 2011). While a similar study has been performed before using a pGL3 vector 
in K562 cells, this cell line naturally expresses high levels of γ globin, and 
therefore any indirect effects of this mutation on HbF or γ globin levels cannot be 
accurately determined (Alsultan et al., 2012). CD34+ cells would be more 
appropriate for this study, as they are erythroid precursor cells and can mirror the 
effects that this mutation would have in developing red blood cells. Indeed, globin 
expression studies have been performed successfully in CD34+ cell lines, and 
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have shown to be an excellent model of sickle cell disease conditions for 
therapeutic studies (Urbinati et al., 2015). 
As the availability of comprehensive medical treatment varies so 
drastically worldwide, it is important to identify and characterize these genetic 
markers in a disease which affects hundreds of thousands yearly in Africa alone 
(Makani et al., 2007). Patients with varying β-globin haplotypes express differing 
disease phenotypes, with the Arab Indian haplotype conveying a particularly 
strong resistance to disease symptoms due to elevated HbF. If the mutations in 
these haplotypes, such as the HBD mutation described in this study, are 
responsible for the protective effects seen in patients, perhaps some of these 
genetic locations can serve as targets for therapeutics in sickle cell disease or 
other blood disorders.  
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Research, Projects, Certifications:  
Co-Author on Journal of Medicinal Chemistry Article - June 2013 
While working with Dr. Phanstiel of the UCF College of Medicine, I was published 
as a co-author on our project, “Development of Flavonoid-Based Inverse 
Agonists of the Key Signaling Receptor US28 of Human Cytomegalovirus.” With 
Dr. Phanstiel’s assistance, I performed and designed much of the organic 
synthesis of the drug derivatives tested in this experiment.  
 
Poster Presentation - April 2013  
I created and presented a poster in the UCF Showcase of Undergraduate 
Research in Orlando, FL. The poster was based on an experiment performed by 
our research group led by Dr. Phanstiel of UCF College of Medicine. The project, 
entitled “Development of Flavonoid-Based Inverse Agonists of the Key Signaling 
Receptor US28 of Human Cytomegalovirus”, described our findings after testing 
the effectiveness of about 30 flavone-based drug derivatives as inverse agonists 
of a specific signaling receptor of HCMV.  
 
Pharmacy Technician Certification - July 2010 
I earned my Pharmacy Technician Certification by studying for and taking the 
Pharmacy Technician Certification Board. This training was helpful when I 
volunteered in the pharmacy department at Winter Park Memorial Hospital. I 
learned information on drug laws and dosage, as well as how to recognize 
generic and brand names of drugs.  
 
 
Undergraduate Science Courses Taken:  
2 Semesters of Biology with Lab 
2 Semesters of Chemistry with Lab 
2 Semesters of Organic Chemistry with Lab 
2 Semesters of Physics with Lab 
Human Gross Anatomy with Lab 
Microbiology with Lab 
Human Physiology 
Molecular Cell Biology 
Immunology 
Graduate Science Courses Taken: 
Biochemistry and Cell Biology 
Human Physiology 
Cellular Organization of Tissues (Histology) 
Medical Immunology 
Pathology 
Biostatistics 
Neuroscience 
 
